Topic: inflammatory bowel disease
Some microRNAs could serve as prognostic markers of Crohn's and open the possibility of developing personalized therapies.
Arena Pharma says cannabinoid receptor-targeting olorinab could help treat the pain associated with Crohn’s disease.
A tool called “polygenic risk scoring” could help physicians identify who faces a high risk of serious diseases.
Blocking the signaling receptor NLRP3 could treat a range of autoimmune disorders, IFM researchers believe.
Gossamer Bio netted $230 million in series B, following its $100 million launch in January, to fund immunotherapy trials against undisclosed targets.
IFM Therapeutics is hiving off its NLRP3 stable into a subsidiary dubbed IFM Tre, which expects to advance its lead asset into phase 1 next year.
The series A will support work to treat disease through the delivery of F. prausnitzii, one of the most abundant species of bacteria in the gut.
Genentech signed a $534 million contract with Microbiotica to pan gut bacteria for biomarkers, live bacterial drugs and new targets for IBD.
Armed with $65 million in series A funding, Celsius will sequence defined patient samples to identify the individual cells responsible for disease.